Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04044534 · ClinicalTrials.gov registry record · Phase 2
Intranasal Insulin for Posttraumatic Stress Disorder
A Phase 2 study of PTSD, sponsored by VA Connecticut Healthcare System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04044534: Recruiting Phase 2 study of PTSD, sponsored by VA Connecticut Healthcare System.
NCT04044534 is a Phase 2 study of PTSD that is actively recruiting participants, run by VA Connecticut Healthcare System. The registered enrollment target is 20 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04044534, a Phase 2 study of PTSD, is actively recruiting participants, sponsored by VA Connecticut Healthcare System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate if intranasal insulin is effective in reducing PTSD symptoms.
Primary Outcome
The five-point CAPS-5 consists of 20 PTSD symptoms rated on a 0-4 scale (total range: 0-80) as follows: (1) 5 Intrusion symptoms (0-20), (2) 2 Avoidance symptoms (0-8), (3) 7 Cognitions and mood symptoms (0-28), and (4) 6 Arousal and reactivity symptoms (0-24). Higher scores represent a worse outcome (i.e., more PTSD symptoms). Findings are reported as change scores. For the medication group: CAPS score changes = CAPS score after taking medication for 1 week - CAPS score just before taking medic
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Intranasal insulin
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 2 |
What NCT04044534 shows while recruiting
NCT04044534 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (93% lower).
The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04044534 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04044534 about?
NCT04044534 is a clinical study titled "Intranasal Insulin for Posttraumatic Stress Disorder". To evaluate if intranasal insulin is effective in reducing PTSD symptoms.
What is the current status of trial NCT04044534?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-10-31. Estimated completion is 2026-05-31.
What conditions does trial NCT04044534 study?
This clinical trial studies the following conditions: PTSD.
What interventions are being tested in trial NCT04044534?
The interventions under investigation include: Placebo (DRUG), Intranasal insulin (DRUG).
Who is sponsoring clinical trial NCT04044534?
This trial is sponsored by VA Connecticut Healthcare System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04044534 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04044534's enrollment target sits among peer trials
20 140th of 154 higher than 10 of 154 other PTSD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PTSD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oxytocin to Enhance Integrated Treatment for AUD and PTSD
RECRUITING · Phase 2
-
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
RECRUITING · Phase 2
-
Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Induction of Dreaming With EEG and Anesthesia for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI